Kaya Ltd. moves to reshape its capital structure

Kaya Limited's proposed preferential issue of up to Rs 49.99 crores involves issuing 18,24,150 equity shares to two non-promoter entities at an issue price of Rs 274.10 per share, which slightly exceeds the SEBI-prescribed floor price of Rs 274.03 ^[1]. Proceeds are earmarked for capital expenditure—explicitly including clinic network expansion—and working capital, with no funds allocated toward debt reduction ^[2].

Allottee Identity

• Axana Estates LLP (Non-Promoter Body Corporate): Allotted 8,45,009 shares. Its ultimate beneficial owners (UBOs) are Mr. Mithun Padam Sacheti, Mr. Siddhartha Sacheti, Mr. Yash Siddhartha Sacheti, and Mr. Arpit Khandelwal ^[3].
• Plutus Investments India Private Limited (Non-Promoter Body Corporate): Allotted 9,79,141 shares. Its UBOs are Mr. Arpit Khandelwal, Mr. Suresh Chander Koolwal, and Mr. Ramesh Siyani ^[3].

Issue Price vs. SEBI Floor Price

• Issue Price: Rs 274.10 per equity share (inclusive of a Rs 264.10 premium), aggregating to Rs 49,99,99,515 ^[1].
• Floor Price: Rs 274.03 per share, calculated in accordance with Chapter V of the SEBI ICDR Regulations based on the higher of the 90-day VWAP (Rs 261.66), 10-day VWAP (Rs 274.03), or the independent valuer certificate from M/s Samarth Valuation Advisory LLP (Rs 274.03) ^[4].

Intended Use of Proceeds

• Clinic Network Expansion & CapEx: 50% of the gross proceeds (~Rs 25.00 crores) is allocated to capital expenditure, which explicitly includes opening new clinics, rental deposits, relocation and renovation of existing clinics, and acquiring medical, diagnostic, and IT infrastructure ^[2].
• Working Capital: 25% of proceeds (~Rs 12.50 crores) is designated for incremental working capital needs, including inventory, vendor payments, employee benefits, and marketing ^[2].
• General Corporate Purposes: Up to 25% (~Rs 12.50 crores) is allocated for general corporate exigencies and contingencies ^[5].
• Debt Reduction: Debt repayment is not included among the objects of the issue ^[2].

Executive Summary

Kaya Ltd announced key executive and board transitions alongside its Q1 FY27 financial results ^[6]. The most critical executive appointment is Mr. Brijesh Goyal as Chief Financial Officer, effective July 11, 2026, succeeding outgoing CFO Mr. Dhariwal ^[7]. Specific remuneration structures (fixed/variable split, equity/ESOP allocations) and fixed contractual tenures for incoming executive leadership were not disclosed in reported filings; however, Non-Executive Independent Director Ms. Vasuta Agarwal was re-appointed for a structured 5-year term (August 3, 2026 to August 2, 2031) ^[8].

Strategically, incoming CFO Brijesh Goyal’s 30-year track record—spanning over 14 years at Reliance Retail and executive finance leadership at Enrich Hair & Skin Solutions ^[7]—aligns directly with Kaya’s imperative to stabilize unit-level clinic profitability amid widening losses ^[6]. However, specific track-record disclosures regarding digital-first technology transformation remain limited in reported announcements.

---

Leadership Transition & Appointment Terms

Kaya Ltd's senior management and board restructuring during Q1 FY27 involves multiple operational and governance positions ^[6]:

• Chief Financial Officer: Mr. Brijesh Goyal appointed CFO effective July 11, 2026 ^[7], following the resignation of former CFO Mr. Dhariwal ^[9].
• Board Re-appointment: Ms. Vasuta Agarwal re-appointed as Non-Executive Independent Director for a 5-year term running from August 3, 2026, to August 2, 2031 ^[8].
• Board Exits: Director Nikhil Nirvan Khattau resigned effective July 31, 2026 ^[10], and Independent Director Om Prakash Manchanda completed his 5-year term on August 2, 2026 ^[11].
• Senior Operations Exits: VP & Head of HR Amrita Chowdhury was relieved effective June 19, 2026 ^[12].

---

Strategic Alignment: Clinic Profitability & Digital Expansion

1. Alignment with Clinic-Level Profitability

• Retail & Chain Clinic Operations Experience: Goyal brings extensive experience across large-scale retail distribution (14+ years at Reliance Retail) and specialized salon/clinic retail networks (Enrich Hair & Skin Solutions) ^[7].
• Financial Turnaround Context: The CFO transition coincides with operating losses, with Kaya reporting a widened Q1 FY27 net loss of Rs 15.18 Crores on revenues of Rs 60.14 Crores ^[6]. The addition of retail finance expertise provides execution capabilities for store/clinic unit economics, lease renegotiations, operating expense rationalization, and capital allocation control ^[7].
• Capital Deferral Management: With Kaya deferring capital raising plans ^[6], incoming financial leadership will be constrained to operating cash flows and disciplined store-level profitability to fund ongoing operations.

2. Digital-First Expansion Focus

• Disclosure Limit on Digital Roadmap: While Goyal's finance background spans large retail enterprises ^[7], specific historical execution credentials around e-commerce, digital omni-channel integration, or direct-to-consumer (D2C) tech-stack scaling under his direct oversight were not explicitly detailed in the appointment disclosures.

---

Key Institutional Implications & Limitations

• Remuneration Disclosure Gap: Remuneration details, performance-linked short-term incentives (STI), long-term incentive plans (LTIP/ESOPs), and compensation benchmarks for the incoming executive management team were not publicly disclosed in the retrieved filings.
• Management Stability Risk: Concurrent departures across finance, human resources, and board-level independent directorships ^[10] highlight organizational reset risks during a period of expanding operating losses ^[6].
• Capital Allocation Uncertainty: With capital raising plans currently deferred ^[6], incoming leadership's immediate test will center on controlling clinic burn rates and sustaining operating liquidity from clinic-level cash flows.

Executive Summary

• ESOP Pool Amendment: The proposed amendment to Clauses 9.1 and 10.3 of the Kaya Employee Stock Option Plan 2021 expands the aggregate option pool by 4,00,000 options (+49.80%), increasing the ceiling from 8,03,204 options to 12,03,204 options ^[13], ^[13].
• Cumulative Share Capital Expansion: Relative to the pre-transaction outstanding base of 1,51,87,609 equity shares ^[14], the preferential issue adds 18,24,150 shares (+12.01%) ^[14], while the total expanded ESOP pool represents 1,203,204 potential shares (+7.92%) ^[13], ^[14]. Combined potential share creation expands pre-transaction share capital by 19.93% (3,027,354 shares) ^[13], ^[14].
• Fully Diluted Ownership Impact: Assuming full exercise of the expanded ESOP pool on top of the post-preferential equity base, total fully diluted capital reaches 18,214,963 shares (derived from ^[13], ^[14]). Existing shareholders face a cumulative dilution of 16.62% ^[13], ^[14], where preferential allottees hold 10.01% ^[14], ^[15] and the total ESOP pool accounts for 6.61% of fully diluted capital ^[13], ^[14].
• Governance Alignment: The expanded 12,03,204 option pool represents 7.07% of the post-preferential basic share capital ^[13], ^[14]. The plan maintains key historical governance limits, including a individual grant cap of 1% of paid-up equity share capital per employee per year ^[13], ^[16] and direct company administration without trust funding ^[16], ^[17].

---

Capital Structure & Dilution Breakdown

The table below outlines the share count trajectory, percentage expansion relative to pre-transaction basic capital, and post-transaction fully diluted ownership structure.

• Notes: Dilution percentages and total fully diluted capital are derived from pre-issue shares (15,187,609) ^[14], preferential shares (1,824,150) ^[14], and total ESOP options (1,203,204) ^[13], assuming a 1:1 option-to-share conversion ratio ^[18].*

---

Key Transaction Terms & ESOP Plan Mechanics

ESOP Pool Amendment Terms

• Clause Revisions: Clauses 9.1 and 10.3 of the Kaya ESOP Plan 2021 are amended to increase the aggregate option limit from 8,03,204 to 12,03,204 options ^[13].
• Conversion Ratio: Each option, upon exercise, entitles the holder to 1 fully paid-up equity share of face value Rs 10 ^[18].
• Option Recycling: Options that lapse, expire, unvest, or are forfeited/cancelled are added back to the pool for future grant without requiring fresh shareholder approval ^[13], ^[18].
• Vesting & Exercise Schedule: Options require a minimum vesting period of 1 year from grant date ^[18] and must be exercised within 1 year post-vesting ^[16].

Preferential Issue Integration

• Transaction Details: Issuance of 18,24,150 equity shares at Rs 274.10 per share (Rs 10 face value + Rs 264.10 premium) ^[1], ^[19], raising Rs 49.99 Crores in cash consideration ^[1], ^[1].
• Allottees: Axana Estates LLP (8,45,009 shares) and Plutus Investments India Private Limited (9,79,141 shares), both non-promoter entities ^[14], ^[15].
• Insider Non-Participation: Promoters, directors, and Key Managerial Personnel (KMP) are not participating in the preferential allotment ^[1].

---

Comparison with Historical Equity Compensation Practices

• Pool Scale relative to Capital Base: The original Kaya ESOP Plan 2021 was approved by postal ballot on January 13, 2022, and had been incrementally amended to 8,03,204 options ^[13], representing 5.29% of pre-issue capital ^[13], ^[14]. The expanded 12,03,204 option pool represents 7.07% of post-preferential basic capital ^[13], ^[14], providing headroom for retention following executive leadership changes ^[13].
• Governance & Individual Limits: The company maintains its historical individual grant restriction under Clause 10.3, capping annual grants to any single employee at 1% of paid-up equity capital on the grant date unless specific shareholder approval is obtained ^[13], ^[16].
• Implementation Structure: The plan continues to be administered directly by the company via fresh share creation, maintaining past practice of avoiding trust-based secondary purchases or loan-financed ESOP structures ^[16], ^[17].
• Pricing Discretion: Exercise price determination remains under the discretion of the Nomination and Remuneration Committee (equal to or below market price on grant date, subject to a floor of Rs 10 face value) ^[16], and exercised shares carry no post-exercise lock-in restrictions ^[17].

---

Analytical Implications

• Economic Balance: While total potential dilution is 16.62% ^[13], ^[14], the dilution is bifurcated between non-dilutive balance sheet expansion (Rs 49.99 Crores equity raise accounting for 10.01% dilution) ^[14], ^[1], ^[15] and non-cash management incentivization (the 12,03,204 option pool accounting for 6.61% fully diluted equity) ^[13], ^[14].
• Pacing of ESOP Dilution: The 6.61% ESOP pool dilution will materialize gradually over multi-year vesting schedules (minimum 1-year cliff) ^[18] rather than immediately upon EOGM approval.

---

Limitations & Disclosure Gaps

• Historical Option Utilization: The EOGM notice does not disclose historical itemized data on options granted, vested, unexercised, or lapsed out of the prior 8,03,204 pool ^[13], ^[13].
• Future Grant Pricing: Specific exercise prices and tranche-wise grant timelines for the 400,000 incremental options remain subject to future Nomination and Remuneration Committee decisions ^[16], ^[16].*